24 results on '"Feyerabend S"'
Search Results
2. ATLAS: A phase 2, open-label study of rucaparib in patients with locally advanced or metastatic urothelial carcinoma
3. Sparing androgen-deprivation therapy upon treatment with abiraterone in patients with chemotherapy-naive castration-resistant prostate cancer: Results from the SPARE-trial (NCT02077634)
4. SURECAP: Survey and Evaluation of Castration Resistant Prostate Cancer (CRPC)
5. Prospective, non-interventional study on the influence of adherence measures on the therapy with Abiraterone Acetate (AA) + Prednisone/prednisolone (P) in patients with metastatic, castration resistant prostate carcinoma
6. PT127 - ATLAS: A phase 2, open-label study of rucaparib in patients with locally advanced or metastatic urothelial carcinoma
7. 1038 - Overall survival with abiraterone acetate plus prednisone vs. docetaxel for the treatment of metastatic hormone-sensitive prostate cancer: An updated network meta-analysis
8. 1035 - Sparing androgen-deprivation therapy upon treatment with abiraterone in patients with chemotherapy-naive castration-resistant prostate cancer: Results from the SPARE-trial (NCT02077634)
9. 762 Results of a phase I/II study in metastatic renal cell carcinoma patients treated with an adjuvant HLA personalized peptide vaccine after resection of metastases and comparison to a contemporary cohort of patients with mRCC
10. 549 Results of a prospective phase I/II randomized trial of peptide-specific vaccination in HLA-A*0201 positive prostate carcinoma patients with biochemical recurrence after radical prostatectomy
11. P081 - Prospective, non-interventional study on the influence of adherence measures on the therapy with Abiraterone Acetate (AA) + Prednisone/prednisolone (P) in patients with metastatic, castration resistant prostate carcinoma
12. P080 - SURECAP: Survey and Evaluation of Castration Resistant Prostate Cancer (CRPC)
13. O11 Final analysis of a phase I/II study with CV9103: An intradermally administered prostate cancer vaccine based on self-adjuvanted mRNA (RNActive®)
14. 429 PCR-based detection of circulating tumor cells in prostate cancer – preliminary experience
15. 76 Clinical and immunological monitoring of a multi-peptide vaccination trial in patients with stage III renal cell carcinoma
16. PCA3 REPRESENTS A CLINICALLY MEANINGFUL PREDICTOR OF PROSTATE CANCER AT REPEAT BIOPSY
17. THE VALUE OF THE PCA3 SCORE IN GUIDING PROSTATE BIOPSY DECISION IN MEN WITH A PRIOR NEGATIVE BIOPSY
18. ANTI-INFLAMMATORY AND ANGIOSTATIC THERAPY IN HORMONE REFRACTORY PROSTATE CANCER (HRPC)
19. 113 ANNEXIN A3 QUANTIFICATION FROM SUPERNATANTS OF URINE AFTER DRE PROVIDES A NOVEL AND CLINICALLY EASY AVAILABLE BIOMARKER FOR THE NON-INVASIVE DIAGNOSIS OF PROSTATE CANCER
20. 570Docetaxel, estramustine and prednisone for the treatment of hormone refractory prostate cancer: A single center experience
21. BONE TURNOVER PARAMETERS ICTP AND PINP ARE PROMISING SERUM MARKERS FOR DIAGNOSIS AND THERAPY MONITORING OF BONE METASTASES IN PROSTATE CANCER PATIENTS
22. 648 ANTI-INFLAMMATORY AND ANGIOSTATIC THERAPY IN HORMONE REFRACTORY PROSTATE CANCER (HRPC)
23. 1018 THE VALUE OF THE PCA3 SCORE IN GUIDING PROSTATE BIOPSY DECISION IN MEN WITH A PRIOR NEGATIVE BIOPSY
24. 280 PCA3 REPRESENTS A CLINICALLY MEANINGFUL PREDICTOR OF PROSTATE CANCER AT REPEAT BIOPSY
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.